Co-Morbidities and Adverse Drug Reactions in HIV
2023 plenary speakers

Learn more about the 2023 plenary presenters.

Impact of comorbidities in aging (followed by roundtable)
Professor Cynthia Boyd, Johns Hopkins School of Medicine, Baltimore, USA

Cardiovascular use of diabetes drugs: mechanisms and indications
Professor Mike Blaha, Johns Hopkins School of Medicine, Baltimore, USA

Inflammation and the pathophysiology of heart failure in people with HIV
Professor Ntobeko Ntusi, University of Cape Town, South Africa

Cancer immunotherapy, checkpoint inhibitors and their toxicities
Professor Elad Sharon, National Cancer Institute, Bethesda, USA

Roundtable: post-acute sequelae of SARS-CoV-2 infection
Speakers: to be confirmed soon
Chairs: Annie Antar, Johns Hopkins University School of Medicine, Baltimore, MD, USA & Michael Peluso, University of California at San Francisco, CA, USA

Speaker and Chair biographies - more to follow soon

Back to top

Annie Antar
Johns Hopkins University School of Medicine, Baltimore, MD, USA

Dr. Antar is an assistant professor of medicine at the Johns Hopkins University School of Medicine whose research focuses on HIV reservoir studies and the pathogenesis of long COVID. She earned her undergraduate degree from Harvard University and an M.D./Ph.D. from Vanderbilt University School of Medicine, where her graduate work focused on mechanisms of pathogenesis of reovirus, which is a model system for double-stranded RNA viruses. She completed both her residency in internal medicine and fellowship in infectious diseases at the Johns Hopkins Hospital.

Dr. Antar's research today focuses on understanding the manifestations and immune correlates of long COVID in people living with HIV. She is the PI of an amfAR-funded, national prospective observational cohort of COVID recovery in people living with HIV and HIV-seronegative people.


Back to top

Michael Peluso
University of California at San Francisco, CA, USA

Dr. Peluso is an infectious disease physician at the University of California, San Francisco. Prior to COVID, his research focus was on the chronic sequelae of HIV infection and HIV cure clinical trials. When the SARS-CoV-2 pandemic emerged, Dr. Peluso led the efforts to implement the Long-term Impact of Infection with Novel Coronavirus (LIINC, pronounced “link”) study at San Francisco General Hospital, based on the hypothesis that COVID could have a long-term impact on health and well-being. LIINC was one of the first post-COVID cohorts in the U.S. and now includes hundreds of individuals with and without Long COVID, many of whom have been followed for more than 2 years. Dr. Peluso is also a co-investigator on a national amfAR-funded study of Long COVID in people with HIV and is responsible for implementation of the UCSF enrolling sites for the NIH’s RECOVER initiative.

Back to top